SVRA241220C2000
- 0.00
- 0.000.00%
Savara Newsroom
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)
Savara Announces New Employment Inducement Grant
Savara Announces Encore Presentation of Results From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the British Thoracic Society Winter Meeting 2024
Express News | Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024
Independent Director of Savara David Ramsay Buys 4.5% More Shares
Insider Purchase: Director at $SVRA (SVRA) Buys 20,000 Shares
Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing
Savara Is Maintained at Buy by HC Wainwright & Co.
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $15
Oppenheimer Keeps Their Buy Rating on Savara (SVRA)
Savara Announces Participation in Upcoming Healthcare Conferences
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $6
Evercore Downgrades Savara(SVRA.US) to Hold Rating, Cuts Target Price to $5
Savara Analyst Ratings
Savara's Promising Molbreevi Launch: Buy Rating Backed by Strategic Initiatives and IMPALA-2 Trial Success
Savara Downgraded to In Line From Outperform at Evercore ISI
Savara Price Target Lowered to $6 From $10 at H.C. Wainwright
Savara | 10-Q: Q3 2024 Earnings Report
Savara: To Initiate Molbreevi Biologics License Application Rolling Submission by End of Year >SVRA
Express News | Savara Inc: Sufficiently Capitalized Through 2Q 2027